Abivax (ABVX) Cash from Financing Activities (2024 - 2026)

Abivax's Cash from Financing Activities history runs 3 years deep, the most recent figure standing at $85464.4 for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 101.04% year-over-year to $85464.4; the TTM figure through Mar 2026 stood at $649.6 million (up 82091.53% YoY), while the FY2025 annual figure was $637.1 million, up 2014.13% from the prior year.
• Cash from Financing Activities was $85464.4 for Q1 2026 at Abivax, up from -$46.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $705.5 million in Q3 2025 to a low of -$46.0 million in Q4 2025.
• Historically, Cash from Financing Activities has averaged $74.6 million across 3 years, with a median of -$6.2 million in 2024.
• Biggest YoY gain for Cash from Financing Activities was 10314.41% in 2025; the steepest drop was 638.73% in 2025.
• A 3-year view of Cash from Financing Activities shows it stood at -$6.2 million in 2024, then plunged by 638.73% to -$46.0 million in 2025, then surged by 100.19% to $85464.4 in 2026.
• The last three Cash from Financing Activities figures came in at $85464.4 (Q1 2026), -$46.0 million (Q4 2025), and $705.5 million (Q3 2025), per Business Quant data.